National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for oesphageal carcinoma or HER-2 negative gastroesophageal junction adenocarcinoma . HTA ID: 21032

Pembrolizumab (Keytruda®) for the first line treatment of adults with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults  whose tumours express PD-L1 with CPS≥10.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/07/2021
Rapid review completed 05/08/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.